Henry Daniell

USPTO Granted Patents = 31 (Patent Applications = 31)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 1.3

ph-index = 8

Forward Citations = 477(Granted Patents)

Location History:

Moscow, ID (US) (1997 - 2003)
Auburn, AL (US) (2006)
Casselberry, FL (US) (2008)
Winter Park, FL (US) (2004 - 2020)
Philadelphia, PA (US) (2020)
Media, PA (US) (2017 - 2024)

Company Filing History:

18 out of 2,597

University of Pennsylvania

University of Central Florida Research Foundation Inc

patents

4. 5 out of 2,930

University of Florida Research Foundation Inc

patents

5. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12059454 - Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders (2024-08-13),

2. 11332754 - Codon optimization for increasing transgene expression in chloroplasts of higher seed plants (2022-05-17),

3. 11246819 - Compositions and methods for inhibiting biofilm deposition and production (2022-02-15),

4. 11241487 - Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders (2022-02-08),

5. 11007247 - Compositions and methods for delivery of bioencapsulated proteins across blood-brain and retinal barriers (2021-05-18),

6. 10889825 - Compositions and methods thereof for down-regulation of genes following oral delivery of an RNAi molecule bioencapsulated within plant cells (2021-01-12),

7. 10865419 - Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes (2020-12-15),

8. 10806775 - Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertensions, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders (2020-10-20),

9. 10752909 - Chloroplasts engineered to express pharmaceutical proteins in edible plants (2020-08-25),

10. 10689633 - Expression of β-mannanase in chloroplasts and its utilization in lignocellulosic woody biomass hydrolysis (2020-06-23),

11. 10676751 - Production and use of plant degrading materials (2020-06-09),

12. 10556932 - Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients (2020-02-11),

13. 10314893 - Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders (2019-06-11),

14. 10233216 - Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients (2019-03-19),

15. 9885055 - Chloroplasts engineered to express pharmaceutical proteins (2018-02-06),

Title: The Innovative Journey of Henry Daniell

Introduction: Henry Daniell, a distinguished inventor based in Media, PA, has made significant contributions to the field of biotechnology through his groundbreaking work in plant molecular biology.

Latest Patents: Henry Daniell holds several patents related to his research in plant-based pharmaceuticals and biopharmaceuticals, including a recent patent for a novel method of producing therapeutic proteins in plant chloroplasts.

Career Highlights: With a career spanning over three decades, Henry Daniell has been at the forefront of developing innovative technologies for the production of affordable and accessible biopharmaceuticals. His work has revolutionized the way therapeutic proteins are produced, making them more cost-effective and sustainable.

Collaborations: Throughout his career, Henry Daniell has collaborated with leading research institutions, pharmaceutical companies, and academic partners to further advance his research in plant molecular biology. His collaborative efforts have led to groundbreaking discoveries in the field of biotechnology.

Conclusion: Henry Daniell's pioneering work in plant molecular biology has not only advanced the field of biotechnology but has also paved the way for the development of novel therapies and treatments. His dedication to innovation and scientific excellence continues to inspire the next generation of inventors and researchers in the field.

This text is generated by artificial intelligence and may not be accurate.